 Nanobiotix NASDAQ: NBTX initiated a new Phase 1 study evaluating NBTXR3 activated by radiation therapy RT for patients with non-small cell lung cancer NSCLC amenable to re-irradiation. The study will investigate the safety and optimal dose of NBTXR3 for non-small cell lung cancer that cannot be treated by surgery inoperable and has come back recurrent. 